{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:21:14Z","timestamp":1791832874244,"version":"4.3.4"},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/COE\/34\/SP15097\/2015"],"award-info":[{"award-number":["BT\/COE\/34\/SP15097\/2015"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011207","name":"New York Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009481","name":"Tata Sons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["nyaspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although biotherapeutic drugs have the potential of transforming the management of many life\u2010threatening diseases, their affordability and accessibility remain an issue. This study offers an overview of the global affordability of biotherapeutic products. For this, prices for 10 representative biotherapeutic products were examined in 40 countries, including high\u2010income countries (HICs), upper middle\u2010income countries (UMICs), lower middle\u2010income countries (LMICs), and low\u2010income countries (LICs). The affordability of these biotherapeutics was calculated based on the World Health Organization\/Health Action International (WHO\/HAI) method. As expected, affordability was found to be better in HICs, followed by UMICs, LMICs, and finally, LICs. Furthermore, based on the trend of per capita income, we predict that in UMICs and LMICs, the affordability of high molecular weight biologics will worsen by 1.5\u00d7 and 2\u00d7 by 2030, respectively, and further by 4\u00d7 and 6\u00d7 by 2040. On the other hand, affordability will stay nearly the same for people living in HICs in the coming decades. Our analysis suggests that it is imperative that measures be taken to make this class of products more affordable and accessible. Governments can contribute by creating conducive policies. Global institutions like the WHO can play a significant role as well. Finally, manufacturers need to invest in and implement manufacturing innovations.<\/jats:p>","DOI":"10.1111\/nyas.15171","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T01:48:24Z","timestamp":1718329704000},"page":"168-178","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Global outlook on affordability of biotherapeutic drugs"],"prefix":"10.1111","volume":"1537","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-4244","authenticated-orcid":false,"given":"Anurag S.","family":"Rathore","sequence":"first","affiliation":[{"name":"Department of Chemical Engineering Indian Institute of Technology  Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Wellcome Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemlata","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering Indian Institute of Technology  Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchir","family":"Raman","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering Indian Institute of Technology  Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Rader R. A.(2018).Biopharma market: An inside look.Pharma Manufacturing.https:\/\/www.pharmamanufacturing.com\/articles\/2018\/biopharma\u2010market\u2010an\u2010inside\u2010look\/"},{"key":"e_1_2_11_3_1","unstructured":"BioSpace. (2022).Biologics market to reach USD 749.62 billion by 2028 says reports and data.https:\/\/www.biospace.com\/article\/biologics\u2010market\u2010to\u2010reach\u2010usd\u2010749\u201062\u2010billion\u2010by\u20102028\u2010says\u2010reports\u2010and\u2010data\/"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.77"},{"key":"e_1_2_11_5_1","unstructured":"Coherent Market Report. (2019).Monoclonal antibodies market. Global industry insights trends outlook and opportunity analysis 2018\u20132026.https:\/\/www.coherentmarketinsights.com\/market\u2010insight\/monoclonal\u2010antibody\u2010therapeutics\u2010market\u20102403"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4753"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075"},{"key":"e_1_2_11_8_1","unstructured":"Roy A.(2019).Biologic medicines: The biggest driver of rising drug prices.Forbes.https:\/\/www.forbes.com\/sites\/theapothecary\/2019\/03\/08\/biologic\u2010medicines\u2010the\u2010biggest\u2010driver\u2010of\u2010rising\u2010drug\u2010prices\/?sh=68f6581018b0"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17742"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-021-00670-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-001410"},{"key":"e_1_2_11_12_1","unstructured":"World Health Organization. (2021).Keeping the 100\u2010year\u2010old promise: Making insulin access universal."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019015"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181c12e53"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.16389"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120441"},{"key":"e_1_2_11_17_1","first-page":"35","article-title":"Adherence and health care costs","volume":"7","author":"Iuga A. O.","year":"2015","journal-title":"Risk Management and Healthcare Policy"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.706289"},{"key":"e_1_2_11_19_1","unstructured":"World Bank. (2021).World Development Indicators\u2014The World by Income and Region.https:\/\/datatopics.worldbank.org\/world\u2010development\u2010indicators\/the\u2010world\u2010by\u2010income\u2010and\u2010region.html"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","unstructured":"World Health Organization. (2021).World Health Organization model list of essential medicines\u2010 22nd list.https:\/\/www.who.int\/publications\/i\/item\/WHO\u2010MHP\u2010HPS\u2010EML\u20102021.02","DOI":"10.1530\/ey.19.13.1"},{"key":"e_1_2_11_21_1","unstructured":"World Health Organization. (2008)Measuring medicine prices availability affordability and price components.World Health Organization and Health Action International.https:\/\/www.who.int\/medicines\/areas\/access\/OMS_Medicine_prices.pdf"},{"key":"e_1_2_11_22_1","unstructured":"World Bank. (2022).World Development Indicators DataBank.https:\/\/databank.worldbank.org\/source\/world\u2010development\u2010indicators"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.knosys.2022.108907"},{"key":"e_1_2_11_24_1","unstructured":"Access to Medicine Foundation. (2022).What are pharma companies doing to expand access to insulin\u2014And how can efforts be scaled up?.Access to Medicine Foundation."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0049-7"},{"issue":"1","key":"e_1_2_11_26_1","first-page":"24","article-title":"Patent expiry dates for biologicals: 2018 update","volume":"8","author":"Derbyshire M.","year":"2019","journal-title":"Generics and Biosimilars Initiative Journal (GaBI Journal)"},{"key":"e_1_2_11_27_1","unstructured":"Generics and Biosimilars Initiative. (2022).Biosimilars of pembrolizumab.Generics and Biosimilars Initiative."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01375"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3593-9"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100506"},{"key":"e_1_2_11_31_1","unstructured":"I\u2010MAK. (2021).Keytruda's patent wall.https:\/\/www.i\u2010mak.org\/wp\u2010content\/uploads\/2021\/05\/i\u2010mak.keytruda.report\u20102021\u201005\u201006F.pdf"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0233-1"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00359-0"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00540-y"},{"key":"e_1_2_11_35_1","volume-title":"International prescription drug price comparisons","author":"Mulcahy A. W.","year":"2021"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3734"},{"key":"e_1_2_11_37_1","article-title":"AbbVie repeatedly hiked Humira, Imbruvica prices and abused patents to keep competitors at bay: Report","author":"Higgins\u2010Dunn N.","year":"2021","journal-title":"Fierce Pharma"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1215\/03616878-10041163"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.033647"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphs.12191"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2006.07.005"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add3055"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092126"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00460-0"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00970"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2076557"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.00123"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-023-00473-z"},{"key":"e_1_2_11_52_1","unstructured":"Harris R. Lawlor R. Poon C. Raj N. &Barron A.(2022)Strengthening regulatory systems in LMICs: Improving the sustainability of the vaccine innovation ecosystem in Africa.Wellcome."},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00376-X"},{"key":"e_1_2_11_54_1","unstructured":"World Health Organization. (2023).WHO model list of essential medicines \u2013 23rd list 2023.https:\/\/iris.who.int\/bitstream\/handle\/10665\/371090\/WHO\u2010MHP\u2010HPS\u2010EML\u20102023.02\u2010eng.pdf?sequence=1"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00575-1"},{"key":"e_1_2_11_56_1","unstructured":"Wellcome IAVI. (2020).Expanding access to monoclonal antibody\u2010based products: A global call to action.Wellcome IAVI."},{"key":"e_1_2_11_57_1","unstructured":"Wellcome. (2023).Scaling up African vaccine manufacturing capacity: Perspectives from the African vaccine\u2010manufacturing industry.Wellcome."},{"key":"e_1_2_11_58_1","first-page":"1367","article-title":"New coalition to increase access to cancer medicines in LMICs","volume":"22","author":"Burki T. K.","year":"2021","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826068.2020.1815061"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826068.2021.1959346"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1012"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4627"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.15171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:02:22Z","timestamp":1721124142000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.15171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/nyas.15171"],"URL":"https:\/\/doi.org\/10.1111\/nyas.15171","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/NYAS.15171\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/NYAS.15171\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/NYAS.15171\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/NYAS.15171\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/NYAS.15171\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"2024-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}